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Myotonic disorders are inherited neuromuscular diseases divided into dystrophic
myotonias and non-dystrophic myotonias (NDM). The latter is a group of dominant or
recessive diseases caused by mutations in genes encoding ion channels that participate
in the generation and control of the skeletal muscle action potential. Their altered function
causes hyperexcitability of the muscle membrane, thereby triggering myotonia, the main
sign in NDM. Mutations in the genes encoding voltage-gated Cl− and Na+ channels
(respectively, CLCN1 and SCN4A) produce a wide spectrum of phenotypes, which
differ in age of onset, affected muscles, severity of myotonia, degree of hypertrophy,
and muscle weakness, disease progression, among others. More than 200 CLCN1
and 65 SCN4A mutations have been identified and described, but just about half of
them have been functionally characterized, an approach that is likely extremely helpful
to contribute to improving the so-far rather poor clinical correlations present in NDM.
The observed poor correlations may be due to: (1) the wide spectrum of symptoms and
overlapping phenotypes present in both groups (Cl− and Na+ myotonic channelopathies)
and (2) both genes present high genotypic variability. On the one hand, several mutations
cause a unique and reproducible phenotype in most patients. On the other hand, some
mutations can have different inheritance pattern and clinical phenotypes in different
families. Conversely, different mutations can be translated into very similar phenotypes.
For these reasons, the genotype-phenotype relationships in myotonic channelopathies
are considered complex. Although the molecular bases for the clinical variability present
in myotonic channelopathies remain obscure, several hypotheses have been put forward
to explain the variability, which include: (a) differential allelic expression; (b) trans-acting
genetic modifiers; (c) epigenetic, hormonal, or environmental factors; and (d) dominance
with low penetrance. Improvements in clinical tests, the recognition of the different
phenotypes that result from particular mutations and the understanding of how a
mutation affects the structure and function of the ion channel, together with genetic
screening, is expected to improve clinical correlation in NDMs.
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NEUROMUSCULAR DISEASES
Neuromuscular diseases are a clinically, genetically, and
biochemically heterogeneous group of more than 80 different
entities (https://www.mda.org/disease/list), some of which
share clinical and dystrophic features (1, 2). The main tissue
affected (some diseases are multisystemic) in these diseases is
the skeletal muscle, which is the organ in charge of locomotion
and other body movements, and contributes to metabolic energy
in multicellular organisms. Malfunction of this organ due to
structural, physiological, or biochemical changes, often caused
by specific genetic mutations, can lead to progressive muscle
weakness/wasting with detrimental health consequences (3).
Clinical features, such as disease severity, progression, age
of onset of symptoms, and prognosis are highly variable (2).
Hereditary neuromuscular diseases have been classified into
several groups depending on the group of muscles targeted
by specific gene mutations. However, clinically different
phenotypes have been found in various patients with different
mutations in the same gene, and even in separate patients
carrying identical mutations (4, 5). The respective genes encode
structural proteins, enzymes, ion channels, some of them
causing muscular dystrophies (1–3). Muscular dystrophies,
which can be inherited as dominant or recessive diseases,
include limb girdle muscular dystrophies, congenital muscular
dystrophies, dystrophinopathies, facioscapulohumeral muscular
dystrophy, Emery–Dreifuss muscular dystrophies, and myotonic
dystrophies. This review will focus on a group of disease that
have been classified within the group of myotonic conditions,
more specifically, the myotonic channelopathies.
MYOTONIC DISEASES
Electrical properties of the skeletal muscle fiber membrane (in a
wide variety of different organisms) are characterized by a high
resting membrane permeability for Cl− ions. These Cl− ions are
transported by Cl− ion channels belonging to the CLC family,
which includes Cl− ion channels and Cl−/H+ exchangers that
are found in all phyla from bacteria tomammals (6–8). The ClC-1
channel is specifically present in skeletal muscle where it accounts
for the chloride conductance, GCl, which amounts to∼80% of the
resting membrane conductance in resting muscles (9–15). Due
to this high conductance and because the equilibrium potential
of Cl− is close to the muscle resting membrane potential, ClC-1
conducts membrane currents that inhibit muscle excitability (6).
The effective Cl− homeostasis is central in the generation and
propagation of the action potential in muscle fibers.
Indeed, it is believed that the prominent role of GCl in action
potential repolarization and membrane potential stabilization
is related to the large cell size and the peculiar t-tubular
system of skeletal muscle. If repolarization were mediated
exclusively by K+ channels (as in most neurons), the extracellular
K+ concentration in the restricted t-tubular space would rise
significantly, leading to depolarization and eventual inactivation
of Na+ channels (15). In fact, the “myotonic runs” of repeated
action potential firing are partially caused by K+ accumulation
(15). Importantly, a still open question is whether ClC-1 channels
are actually preferentially located in the t-tubularmembrane or in
the surface sarcolemma (16–19).
It is well-known that excitation-contraction coupling,
triggered by the nerve-impulse induced muscle action potential,
is orchestrated by multiple factors (mainly ion channels) that
lead to the release of Ca2+ from the sarcoplasmic reticulum.
However, changes in the electrical properties of an excitable
muscle, that can occur by both acquired or inherited bases,
are well-recognized causes of muscle malfunction in humans
(20). Reduction in muscle excitability may be the major
cause of muscle weakness leading to fatigue (21), while
hyperexcitability may lead to a sustained bursts of discharges
that cause involuntary after-contractions, a phenomenon known
as myotonia, the classical and leading sign of several hereditary
diseases of skeletal muscle (20, 22). Therefore, myotonia is a
clinical sign of skeletal muscle that results from an increased
excitability of the muscle fiber membrane such that a single
nerve stimulus triggers a burst of repetitive action potentials
causing a delay in the temporal course of muscle relaxation (23).
In patients, this condition can be detected as both electrical
and clinical myotonia (24, 25). Electrical myotonia is detected
on electromyographic (EMG) tests as repetitive muscle fiber
potential discharges, with waxing and waning frequency and
amplitude with a firing rate between 20 and 80Hz, while clinical
myotonia is physically demonstrated by slowedmuscle relaxation
during repetitive hand grip, eye closure, or after tapping various
muscles, such as the finger extensors (26).
Symptomatically, patients experience myotonia as stiffness
at the beginning of motion, better exemplified during initial
attempts at relaxation of hand grip (grip myotonia) and
following percussion of the muscle located in the bases of the
thumb (percussion myotonia) (27). Myotonia can ameliorate
with repeated movements, a phenomenon known as warm-
up, but also, it can get worse with activity and become
paradoxical (28, 29).
Diseases associated with this sign are collectively termed
myotonias and according to other clinical features (progressive
muscle wasting and weakness, dystrophic changes), they are
classified as: (1) dystrophic myotonias (DM) and (2) non-
dystrophic myotonias (NDM). Myotonic dystrophy type 1
(DM1) and type 2 (DM2), caused by the expansion of unstable
microsatellites, belong to the first group, and are beyond the
scope of this review. A group of five diseases, collectively called
myotonic channelopathies, caused by mutations in voltage-gated
Na+ and Cl− channel genes, belong to the second group (30).
This review is focused on the latter group of diseases.
NON-DYSTROPHIC MYOTONIAS
Dominantly or recessively inherited disorders caused by
ion channel dysfunction include myotonia congenita (MC)
(Thomsen’s disease and Becker type myotonia), paramyotonia
congenita (PC), hyperkalemic periodic paralysis (hyperPP) with
myotonia and the sodium channel myotonias (SCM). These
diseases show distinctive clinical features that allow separating
them from the myotonic dystrophies. They are divided into
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two groups: the chloride and the sodium channelopathies. The
first group, called myotonia congenita (MC), is subdivided in
Thomsen’s disease and the Becker generalized myotonia. The
other group of three diseases listed above belong to the sodium




For precise control of muscle contraction by nerve activity, in
normal conditions, a single nerve action potential triggers only a
single muscle action potential. This is to a large extent guaranteed
by the large GCl that aids in repolarizing the action potential and,
once repolarized, continues to stabilize the membrane potential,
preventing thereby the insurgence of a train of action potentials
(33). Reduction of the Cl− conductance in the skeletal muscle
causes myotonia congenita (MC), the most common ion channel
disease (34). The first description of this pathology dates back
to the late nineteenth century, when Danish physician Asmus
Julius Thomas Thomsen described it for himself and for some
of his family members, with an autosomal dominant inheritance
pattern (35). The dominant form of MC was called Thomsen’s
disease (DMC) after that (36). Almost a century after that
first description, German professor Peter Emil Becker described
a MC variant with autosomal recessive inheritance pattern, a
variant that was called recessive generalized myotonia or Becker
myotonia (RMC) (37).MC is electrophysiologically characterized
by presenting increased excitability of the muscular fiber, which
is due to repetitive action potentials of the muscle membranes;
this is reflected in clinical myotonia, muscular stiffness (that is
worse after rest) and hypertrophy (38, 39). Myotonia in MC
is clinically highly variable, ranging from myotonic discharges
only detectable on the EMG test to disabling muscle stiffness
at an early age (5). The leg muscles are commonly affected
and handgrip myotonia is detected in about ¾ of patients
(22). Almost every skeletal muscle in the body might show
muscular stiffness, but it is ameliorated by exercise (warm-
up phenomenon). The clinical picture depends on whether
the disease is inherited as autosomal dominant or autosomal
recessive. RMC is more common (in most countries) and severe
than DMC (5, 24, 25, 40–42). In DMC, age of onset is usually at
birth or very early in infancy. The child might show unusually
defined muscles in the extremities, delayed relaxation of the
eyelids after forceful closure following sneezing or during crying,
and hypertrophy is rare in childhood but common in adulthood
(31, 43). Severity varies from mild to moderate, there is no
progression of the symptoms, and patients can experience a
normal life (43). In RMC, age of onset is usually later than in
DMC (25, 43), but it has been also reported that age of onset could
be earlier in RMC (44). Myotonia is generalized with moderate
to pronounced hypertrophy, where many patients use to have
a body-builder appearance due to hypertrophy triggered by the
involuntary after-contractions (20, 43). Myotonia is more severe
in the recessive variant and usually, typical transient muscular
weakness (lasting from seconds to as long as 30min) is also
observed (10, 45), which may lead to recurrent falls (31, 34).
Muscle strength is normal in this variant but the disease slowly
progresses in some patients (34, 46).
Sodium Channelopathies
The upstroke of the action potential is mediated by opening of
voltage-gated Nav1.4 sodium channels that generate an inward
Na+ current that renders the cells positive inside (depolarization)
(31). Malfunction of these channels cause several human
hereditary diseases of the skeletal muscle. Diseases belonging
to this group are: paramyotonia congenita (PC), hyperkalemic
periodic paralysis (HyperPP) with myotonia and the sodium
channel myotonias (SCM). Similar to MC, these diseases are
characterized by increased muscle membrane excitability that
leads to repetitive action potentials; however, the underlying
physiological defect is different compared with the chloride
channelopathies (24, 47). Symptoms in sodium channelopathies
are episodic and vary from patient to patient and also from
time to time on each affected individual (47). Clinical myotonia,
affecting hands, face, upper and lower extremities is generalized,
going from absent to very severe, depending on the disease, and
usually gets worse with exercise; while electrical myotonia may
be diffusely present in all muscle and in some cases, may worsen
due to cold exposure, which may also induce weakness in some
patients, and clinical myotonia. The length of the attack is very
variable, lasting from minutes up to 7 days. Muscle hypertrophy
is not as common as in the chloride channelopathies, but it is
present in variable degrees in some patients. Age of onset of the
disease is usually in the first decade and it might progress later in
life in some patients (25, 27, 48–50).
PC was first described by Eulenburg (51). Age of onset of
first symptoms is at birth or during the first decade of live,
affecting mainly the muscles from neck, face and upper limbs.
As indicated by its name, PC shows paradoxical myotonia, which
gets worse with repeated movements and/or cold exposure. PC
show variable weakness, which becomes evident after myotonic
stiffness attacks, the major symptom in PC (20, 47). PC
patients may experience HyperPP weakness-like phenotype after
pronounce cooling or vigorous exercise (20).
In HyperPP, age of onset of the first symptoms (recurrent
episodes of weakness as the main symptom) is during childhood.
Symptoms are triggered by ingestion of K+-rich food, rest after
vigorous exercise, and other environmental factors (47, 52–54).
The episodes of weakness vary from minutes to several hours,
with normal weakness between attacks. Patients affected with
HyperPP frequently have myotonia (symptomatically in 12.5%
or by EMG in 50% of patients), which can be from mild to
moderate, particularly with the onset of a weakness attack.
Some patients develop paramyotonia, highlighting the extensive
clinical overlapping between these two conditions (20, 47, 53, 55).
SCM is less well-defined with onset of first symptoms
from childhood, as in acetazolamide-responsive myotonia, to
adolescence, as in myotonia fluctuans (47). Myotonia can be
present frommild (in myotonia fluctuans) to severe (in myotonia
permanens affecting swallowing and breathing); no periodic
paralysis has been observed in SCM patients, while there are
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some patients that have shown potassium-aggravated myotonia
(K+-sensitive myotonia) (20).
GENETICS AND MUTATION IN MYOTONIC
CHANNELOPATHIES
Chloride Channelopathies
As mentioned above, MC is the most common hereditary ion
channel disorder in humans, showing a prevalence between
1:23,000 and 1:50,000 for the recessive form (Becker Myotonia),
while the dominant form (Thomsen’s disease) is a bit less
common in most countries (40, 42, 56). Both conditions are
caused by mutations in the chloride voltage-gated channel 1
(CLCN1) gene (10, 57–59), which is located in chromosome
7q35 and encodes the voltage-gate chloride channel (ClC-1),
belonging to the CLC family of chloride channels (60, 61).
Although the pathogenesis of MC is not fully understood, it is
well-known that mutations in CLCN1 produce a reduction of
the Cl− conductance that leads to membrane hyperexcitability,
triggering repetitive action potentials (24, 25, 31). The channel
conducts chloride ions over the entire physiological voltage
ranges and is the major mediator of chloride conductance
in skeletal muscle (13, 14, 31, 62, 63). Two subunits of the
channel are required to come together to form the functional
channel, and thus, work as double-barreled homodimers (64–
66). The CLCN1 gene has 23 exons, with more than 200 different
mutations described in this disease (4, 41, 43, 67, 68) (http://
www.hgmd.cf.ac.uk/ac/index.php). Mutations are found through
the entire gene sequence, being present in the N-terminal,
transmembrane, and C-terminal domains of ClC-1. Different
types of mutations have been found in theCLCN1 gene, including
nonsense, splice-site, missense, frameshift (insertion/deletions),
and deletion/duplication mutations, with exon eight becoming a
hot spot for DMC (20, 41, 67, 69–71). The recessive inheritance
is conceptually explained by a loss-of-function effect caused by
the mutations without significantly impacting on the formation
or function of dimeric ClC-1 channels. On the other hand, the
dominant inheritance is explained by a dominant-negative effect
of mutated subunits on heteromeric mutant/WT channels. Most
of the 200 different mutations identified and described behave
as recessive, with the majority of the patients being compound
heterozygous (carriers of two different recessive mutations).
Only about 27 mutations have been associated with DMC,
while about other 59 mutations have an unclear inheritance
pattern, are sporadic or have been also shown to display
a recessive inheritance pattern (http://www.hgmd.cf.ac.uk/ac/
index.php). Therefore, a clear distinction between dominant and
recessive mutations is not always possible (5, 39, 41, 43, 72–74).
Thus, far, there is no other clinical phenotype associated with
mutations in the CLCN1 gene.
Sodium Channelopathies
Na+ channelopathies are not as common as Cl− channelopathies,
showing a combined prevalence of about 1:100,000 (42). These
disorders are caused by mutations in the sodium voltage-
gated channel alpha subunit 4 (SCN4A) gene, which is located
in chromosome 17q23 and encodes the voltage-gated sodium
channel (Nav1.4) of skeletal muscle (75–77). They are a
heterogeneous group of autosomal dominant disorders with high
penetrance (20, 55). Mutations in SCN4A cause disruption of
fast inactivation of the channel, which can be incomplete or
slowed (78–80), leading to repetitive action potentials (myotonic
runs) and consequent intracellular sodium accumulation that
depolarizes muscle cells and can lead to inactivation of the
Na+ channels (25, 31, 32, 47). Depending if depolarization is
mild or not, myotonia or paralysis might appear, respectively
(81). Nav1.4 is a channel formed by a single unit of Nav1.4
protein, which contains four repeated domains (DI-DIV), each
one consisting of six transmembrane segments (S1–S6). The
loops between S5–S6 segments from the four domains come
together to form the ion-conducting pore, acting as a selective
filter. Meanwhile, the S4 segment of each domain is in charge
of sensing the voltage changes (31, 32, 47). The SCN4A gene
has 24 exons, with about 83 different mutations described in
the gene, but only about 65 of them have been associated with
myotonia (40, 82–86) (http://www.hgmd.cf.ac.uk/ac/index.php).
All SCN4A mutations correspond to missense mutations, with
the single exception of a deletion/insertion mutation located
in the splice site in intron 21 (87, 88). All SCN4A myotonia
mutations studied produce a gain-of-function effect of Nav1.4,
resulting in defects of channel inactivation or enhancement of
activation, which explain the dominant inheritance pattern of the
diseases (20, 82). Mutations have been located through the entire
gene sequence, but depending on the disease, they tend to group
differentially. For instance, mutations associated with HyperPP
with myotonia are generally located in the inner regions of
the transmembrane segments or in the intracellular interlinking
loops in repeat domains DII and DIV of the channel, eliciting a
persisting inward sodium current, which impairs repolarization
and increases membrane excitability (82, 89). In PC, mutations
have been found throughout the gene, with exon 24 appearing to
be a hot spot (90), but their impairment of fast inactivation is less
notorious than the one associated with HyperPP (81). Regarding
SCM, although mutations have been found throughout the gene,
there are more likely located in the N terminus of the channel,
in repeat domain D1, particularly in the inactivation gate (82).
Interestingly, in recent papers, the authors describe several
SCN4A mutations, previously reported in unrelated myotonia-
positive families, new or de novo mutations, that contribute
to apnea during the physiological stress of seizures, severe
respiratory failure or associated with paradoxical vocal fold
motion (PVFM) (91–93). Neonatal laryngospasm and unusual
distribution of myotonia and other NDM signs have also been
reported in several NDM patients, who have been shown
to carry different SCN4A mutations, such as G1306E, I693T,
A799S, N1297K, and T1313M (although not all patients that
carry these mutations show childhood or neonatal respiratory
problems) (78, 94–99). This expands the spectrum of phenotypes
associated with mutations in the SCN4A gene. In addition
to myotonic diseases associated with SCN4A mutations, other
diseases, that are beyond the scope of this review, also present
mutations in this gene, such as: hyperkalemic periodic paralysis
without myotonia (HyperPP), hypokalemic periodic paralysis
(HyppoPP), normokalemic periodic paralysis (NormoPP), and
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congenital myasthenic syndrome (CMS) (20, 82). Recently, it has
also been suggested that a subset of cases with sudden infant
death syndrome (SIDS) might be due to SCN4A mutations, as
one report (and the only one thus far) has found novel or very
rare functionally disruptive SCN4A genetic variants associated
with SIDS, although the authors indicate that new studies in other




In order to provide accurate prognostic information to the
patients and families affected with a hereditary disease, it is
essential to have appropriated genotype-phenotype relationships.
In the case of the non-dystrophic myotonias, this has been
extremely difficult mainly due to two factors: (1) the wide
spectrum of symptoms and overlapping phenotypes present in
both groups (Cl− and Na+ myotonic channelopathies) (24,
25, 47), and (2) both genes, CLCN1 and SCN4A, present
high genotypic variability, with more than 200 or 65 different
mutations already described, respectively (http://www.hgmd.
cf.ac.uk/ac/index.php) (23, 43). Although many mutations
cause a unique and reproducible phenotype in all patients,
some SCN4A and CLCN1 mutations cause similar phenotypes.
Most worryingly, for several mutations, very different clinical
phenotypes have been found in different carriers of the same
mutation (23, 25, 47, 101), severely compromising the genotype-
phenotype correlation in NDM. Another important limitation
for the improvement of genotype-phenotype correlations has
been the lack of a sufficient number of individuals carrying
each mutation (23), in particular in the case of novel mutations
[such as the very recent study that described seven novel CLCN1
mutations (68)], which makes the situation even more complex,
not without mentioning all those cases that show myotonia or
a myotonia-like phenotype but in which the mutation has not
been found. It is worth mentioning though, that correlation of
mutations with the clinical phenotype gives insights into the
pathophysiology of human channelopathies, and although some
correlation exists between specific mutations and the associated
clinical manifestations, this is vague (47).
The poor correlations are most evident in Cl−
channelopathies, where the same mutation can be inherited as
dominant or recessive with different clinical manifestations,
for example, F167L (39, 67, 68, 102, 103), A313T (67, 104),
or W433R (44) (see Table 1). By recording and analyzing the
ion currents of heterologously expressed mutant channels
in different in vitro expression systems (Xenopus oocytes or
HEK cells), much progress has been made in understanding
how specific mutations affect the function of a particular ion
channel, in providing insights onto the mechanism for the
inheritance pattern, but also in the role that the voltage-gated
ion channels play in excitable tissues (20, 25, 105). These
analyses have contributed to improve to some extent, the clinical
correlations through a better understanding of the channel
dysfunction and its associated clinical picture. Nevertheless,
of the more than 200 or 65 different Cl− and Na+ mutations,
only about 80 and 30 different mutations, respectively, have
been functionally characterized (http://www.hgmd.cf.ac.uk/ac/
index.php). However, these functional analyses have contributed
to understand in a better way the recessive or dominant
behavior of different CLCN1 mutation than the overlapping
phenotypes and clinical variability shown by some specific
mutation (39, 67, 102, 103). For instance, in general, it has been
reported that several recessively inherited CLCN1 mutations
show biophysical defects like reduced open probability, reduced
single-channel conductance, or biochemical instability, in a
manner that does impinge in a significant manner on the
formation or function of heteromeric mutants/WT channels
(13, 106, 107). A simple example are early stop codon mutations
which do not result in the expression of ClC-1 subunits (108). In
this regard, it has to be remembered that to provoke myotonia,
GCl has to be lowered below roughly 30% (109–112). On the
other hand, several dominantly inherited CLCN1 mutations
have been shown to exert in vitro a dominant negative effect
in co-expression with WT (39, 58, 64, 107, 113, 114). In many
cases the dominant negative effect is mediated by a shift of the
open probability of the “common gate” to more positive voltages
(107, 113, 114). These properties provide a rational to explain the
dominant inheritance. However, this does not explain the clinical
variability observed in both RMC and DMC. Interestingly, there
is a group of 12 CLCN1 mutations (see Table 2) in which the
functional in vitro analyses have not been able to demonstrate
differences with the WT channel, suggesting the presence
of additional factors in skeletal muscle fibers, not present
in oocytes/HEK cells, that are involved in the disease. Such
factors could be related, for example, to subcellular targeting,
a still open question for ClC-1 (18, 19). For these mutations,
a powerful experimental approach would be the generation
and analysis of knock-in mice carrying the myotonia-related
CLCN1mutations, since myotonic mice are an established model
for chloride channel myotonia (13, 115). Such knock-in mice
could provide important information that cannot be obtained in
heterologous expression systems. Additionally, patient derived
induced pluripotent stem cells (iPSCs), combined with suitable
myogenic differentiation (116), or the use of CRISPR/Cas
approaches in order to correct (genome editing) specific
mutations (followed by evaluating the off-target activities of
CRISPR/Cas systems), might provide future avenues of studying
the impact or correction of ion-channel mutations. However, in
particular for CLCN1, these approaches are complicated by the
fact that CLCN1 expression (in vivo) requires fully differentiated
and innervated muscle fibers (117). Importantly, many of these
approaches also apply for the study of sodium channel mutations
(see below).
Clinical correlations in sodium channel myotonic disorders
are not as complex as the chloride channel myotonic
disorders. As with MC, functional analyses in Na+ myotonic
channelopathies have contributed to the understanding of the
pathophysiological mechanism and improvement of clinical
correlation, which are more accurate in this case. These analyses
have been able to provide that Na+ channel mutations have
four major effects on Nav1.4 function: (1) enhanced activation;
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TABLE 1 | CLCN1 mutations behaving as dominant/recessive.
Mutation Inheritance Phenotype Functional effects in heterologous expression
systems (references of functional evidence)
References of
genetic evidence
c.501C>G, p.F167L Recessive Generalized Myotonia (compound heterozygous) From very small shift of po to not different from WT
(103, 118)
(39, 102)
Dominant Thomsen’s like phenotype (67, 103)
c.689G>A, p.G230E Recessive Generalized Myotonia (compound heterozygous) Dominant negative effect, dramatic change in ion
selectivity (58, 114)
(38)
Dominant Thomsen’s disease (104, 119)
c.803C>T, p.T268M Recessive Generalized Myotonia (compound heterozygous) Changed po of the common gate (120) (121)
Dominant Thomsen’s disease (119)
c.920T>C, p.F307S Recessive Generalized Myotonia (compound heterozygous) Dominant negative effect, shifted the voltage
dependence of po to positive potentials (74)
(122)
Dominant Thomsen’s disease (74)




c.950G>A, p.R317Q Recessive Generalized Myotonia (compound heterozygous) Shifted gating to positive potentials (113) (62)
Dominant Thomsen’s disease (39)
c.1013G>A, p.R338Q Recessive Generalized Myotonia (compound heterozygous) Shifted the voltage dependence of po to positive
potentials (118)
(102)
Dominant Thomsen’s disease (38)
c.1297T>C, p.W433R Recessive Generalized Myotonia (compound heterozygous) Not determined (44)
Dominant Thomsen’s disease
c.1478C>A, p.A493E Recessive Generalized Myotonia (compound heterozygous
and homozygous)
Unavailable (123)
Dominant Thomsen’s disease (123)
c.1592C>T, p.A531V Recessive Generalized Myotonia (compound heterozygous) Not determined (5, 124)
Dominant Thomsen’s disease (5)
c.1667T>A, p.I556N Recessive Generalized Myotonia (homozygous) Shifted the voltage dependence of po to positive
potentials with minimal dominant negative effect (74)
(104)
Dominant Thomsen’s disease (incomplete dominance)
c.1936A>G, p.M646V Recessive Generalized Myotonia (compound heterozygous) Unavailable (123)
Dominant Thomsen’s disease (123)
c.2680C>T, p.R894X Recessive Generalized Myotonia (compound heterozygous) Large reduction, but not complete abolition of chloride
currents, and weak dominant effects (39)
(39, 121)
Dominant Thomsen’s disease (39, 102)
(2) impaired slow inactivation; (3) impaired fast inactivation;
and (4) accelerated recovery from fast inactivation. But, as
with the CLCN1 mutations, while these effects explain the
dominant behavior of the mutations (dominant gain-of-function
effect), they contribute little to the explanation of the clinical
variability seen in this group of NDM. Nevertheless, it is
well-accepted that: (1) a large fraction of persistent current
and an incomplete slow inactivation of the channel may cause
a strong long-lasting depolarization, providing the bases for
weakness in HyperPP; (2) a slowing of fast inactivation and an
incomplete closure of the channel may explain the paradoxical
myotonia characteristic of PC; and (3) an increased persistent
fraction and/or slowing of fast inactivation might explain the
slight depolarization that causes myotonia in affected patients
with SCM [reviewed in (47)]. But this does not explain the
clinical variation observed in different patients, or even the
overlapping symptoms seen with MC. In the case of SCN4A
mutations, to the best of our knowledge, there have not
been reported mutations that, functionally, behave as the
WT channel.
Interestingly, there have been few patients carrying a SCN4A
mutation who have been shown to carry a second mutation in
CLCN1 (see Table 3). These patients have shown an exacerbated
or atypical Na+ channel disease phenotype, suggesting that both
mutation may act synergistically to influence the clinical and
neurophysiological phenotype observed in those patients (130).
For many years, it was common practice to screen just one
among CLCN1 or SCN4A genes, based on the presumptive
clinical phenotype. It is thus likely that a significant group of
the first (or even some of recent cases) NMDs cases (with
atypical/unclear phenotype, unclear inheritance pattern or dual
inheritance-dominant or recessive) with molecular diagnosis,
carry a second mutation in any of this ion channel genes, and,
maybe even in other loci. Based on this and suggested by many
authors, the recommendation is that in those NDM cases with
atypical phenotypes or inheritance pattern, both CLCN1 and
SCN4A genes are screened. However, thanks to new technologies
and price reduction, it might now be possible to carry out
deep sequencing, such as whole genome sequencing or gene-
targeted sequencing (by next generation sequencing-NGS), in
these patients. These new approaches not only would allow to
properly screen these genes and genotype NDM patients, but
also, could contribute to identify gene modifiers that might be
involved in modulating their phenotypes. In fact, very recently it
was published the first report using whole genome sequencing
for screening the CLCN1 gene in RMC patients (131). These
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TABLE 2 | CLCN1 mutations behaving similar to ClC-1 WT in in vitro expression systems.
Mutation Phenotype Functional analysis result Heterologous expression system References
c.209C>T, p.S70L Compatible with RMC Macroscopic current amplitudes and current slopes
comparable to WT
HEK293 cells (125)
c.244A>G, p.T82A Compatible with RMC No effect on chloride currents, very similar to WT tsA201 cells (126)
c.313C>T, p.R105C Compatible with RMC Chloride currents similar to WT HEK293 cells, Xenopus oocytes (103, 106)
c.352T>G, p.W118G Myotonia positive patients Currents amplitudes similar to WT HEK293 cells (127)
c.449A>G, p.Y150C Compatible with RMC Currents indistinguishable from WT Xenopus oocytes (107)
c.501C>G, p.F167L Compatible with RMC or DMC Currents very similar to WT HEK293 cells, Xenopus oocytes (103, 106)
c.782A>G, p.Y261C Compatible with RMC Currents indistinguishable from WT Xenopus oocytes (107)
c.979G>A, p.V327I Compatible with RMC Currents very similar to WT Xenopus oocytes (61)
c.1357C>T, p.R453W Compatible with RMC No effect on chloride currents, very similar to WT tsA201 cells (126)
c.1412C>T, p.S471F Myotonia positive patients Electrophysiological parameters similar to WT Xenopus oocytes (128)
c.1883T>C, p.L628P Compatible with RMC Currents very similar to WT tsA201 cells (129)
c.2533G>A, p.G845S Myotonia positive patients Currents indistinguishable from WT ClC-1 tsA201 cells (108)
RMC, recessive myotonia congenita; DMC, dominant myotonia congenita; WT, wild type; NDM, non-dystrophic myotonia.
TABLE 3 | Simultaneous mutations in CLCN1 and SCN4A in NDM patients showing an atypical phenotype.









Patient 1. Myotonic discharges with type II electrophysiology
pattern. PC-like phenotype. Some signs of MC
Patient 2. Myotonic discharges with type II electrophysiology
pattern. PC-like phenotype. Some signs of MC
Patient 3. Myotonic discharges with type III electrophysiology
pattern. SCM-like phenotype. Some signs of MC
ND (132)
SCN4A c.3870C>A, p.F1290L
CLCN1 c.2848 G>A, p.E950K
Myotonic discharges with type III electrophysiology pattern.
SCM-like phenotype with periodic paralysis





Mild NDM phenotype. SCM-like phenotype HEK293 cells/SCN4A = impairment of




Patient with severe myotonia and without fulminant paralytic
episodes
HEK293 cells/SCN4A = enhanced
activation-CLCN1 = ND
(135)
MC, myotonia congenita; PC, paramyotonia congenita; SCM, sodium channel myotonias; NDM, non-dystrophic myotonia; ND, not determined.
new approaches could be very useful to screen those patients
with atypical phenotypes and those in which the effect of
the identified mutation does not differ from the wild-type
channel (see below).
The molecular bases for the clinical variability present
in myotonic channelopathies remain obscure. Yet, a deeper
understanding is needed to improve genotype-phenotype
correlations. Several hypotheses have been put forward to explain
the clinical variability, which include: (a) differential allelic
expression; (b) trans-acting genetic modifiers; (c) epigenetic,
hormonal or environmental factors; and (d) dominance with
low penetrance (20, 47, 136–138). These putatively acting
(alone or in combination) mechanisms might contribute to
explain why the same mutation causes different degrees of
channel dysfunction in different patients (74), and therefore
elicit a modulation in the NDM phenotype. Importantly, to
the best of our knowledge, none of these possibilities has
been established experimentally in NMD patients or are under
current investigation.
The above considerations suggest that it is not only important
to study as many individuals or mutations as possible, but also
to try to obtain functional data for all mutations. In addition,
deeper insight is expected from bioinformatics and structural
approaches combined with information on nearby mutations,
aided by the recently obtained 3D structure of the ClC-1
protein (139, 140). The results of these studies, in addition to
explaining in a better way the different symptoms associated
with particularmutations, would contribute to improving clinical
correlations. Improvements in clinical tests, the recognition of
the different phenotypes that result from particular mutations
and the understanding of how a mutation affects the structure
and function of the ion channel, together with genetic screening,
is expected to improve clinical correlation in NDMs, which could
ultimately be translated into better clinical management and to a
better quality of life of affected patients and their families.
Finally, a solid knowledge of functional defects caused by
specific mutations might help in the development of selective
drugs targeted at a correction of such effects. For example,
Frontiers in Neurology | www.frontiersin.org 7 January 2020 | Volume 10 | Article 1404
Morales and Pusch Complex Correlations in Myotonic Channelopathies
gating modifier drugs could be developed to invert the shift of
the voltage-dependence of some dominant CLCN1 mutations.
Several small molecule compounds are indeed known to interfere
with the open probability of ClC-1 channels, suggesting the
principal feasibility of such an approach (141, 142). In particular,
derivatives of clofibric acid have been shown to shift the voltage-
dependence of ClC-1 and the related ClC-0 to more positive
voltages (141–143). The development of novel molecules that
specifically bind to and stabilize the open state of the channel
could be aided by the recent determination of the structure of
ClC-1 (139, 140). Another possible line of intervention regards
patients with mutations that lead to protein folding defects.
Such defects might be treated with small molecules that act
as “correctors.” Such an approach is already in clinical use in
other diseases, such as cystic fibrosis (144). Since correctors are
assumed to stabilize the folded state of the channel, it might be
tempting to start the search of correctors using ClC-1 inhibitors,
like 9-anthrazene carboxylic acid (9AC) (143). However, all
known ClC-1 inhibitors are of rather low affinity and quite
unspecific (8). Therefore, such correctors are likely only to be
discovered using high-throughput screening, as done for the
most common CFTR mutation causing cystic fibrosis (118).
Indeed, generic correctors, such as 4-phenylbutyrate, miglustat,
and sildenafil have proven unsuccessful for cystic fibrosis (118).
For preparing this review, we (both authors) have used our
personal historical literature database of publications regarding
CLCN1 and SCN4A related myotonia, as well as PubMed
searches using the keywords “myotonia AND (CLCN1/CLC-1,
SCN4A/Nav1.4, apnea, laryngospasm).”
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